Update of inflammatory proliferative retinopathy: Ischemia, hypoxia and angiogenesis

Rivera, 2017, Retinopathy of prematurity: inflammation, choroidal degeneration, and novel promising therapeutic strategies, J Neuroinflamm, 14, 165, 10.1186/s12974-017-0943-1 Villacampa, 2015, Proliferative retinopathies: animal models and therapeutic opportunities, Curr Neurovasc Res, 12, 189, 10.2174/1567202612666150311113535 Portillo, 2014, Proinflammatory responses induced by CD40 in retinal endothelial and Muller cells are inhibited by blocking CD40-Traf2,3 or CD40-Traf6 signaling, Invest Ophthalmol Vis Sci, 55, 8590, 10.1167/iovs.14-15340 Engerman, 1995, Retinopathy in animal models of diabetes, Diabetes Metab Rev, 11, 109, 10.1002/dmr.5610110203 Smith, 1994, Oxygen-induced retinopathy in the mouse, Invest Ophthalmol Vis Sci, 35, 101 Tang, 2011, Inflammation in diabetic retinopathy, Prog Retin Eye Res, 30, 343, 10.1016/j.preteyeres.2011.05.002 Antonetti, 2012, Diabetic retinopathy, N Engl J Med, 366, 1227, 10.1056/NEJMra1005073 Antoniades, 2009, The CD40/CD40 ligand system: linking inflammation with atherothrombosis, J Am Coll Cardiol, 54, 669, 10.1016/j.jacc.2009.03.076 Gabay, 2010, IL-1 pathways in inflammation and human diseases, Nat Rev Rheumatol, 6, 232, 10.1038/nrrheum.2010.4 Chakrabarti, 2007, CD40-40L signaling in vascular inflammation, J Biol Chem, 282, 18307, 10.1074/jbc.M700211200 Karpusas, 1995, 2 A crystal structure of an extracellular fragment of human CD40 ligand, Structure, 3, 1031, 10.1016/S0969-2126(01)00239-8 Li, 2008, CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury, Am J Pathol, 172, 1141, 10.2353/ajpath.2008.070633 Senhaji, 2015, The contribution of CD40/CD40L Axis in inflammatory bowel disease: an update, Front Immunol, 6, 529, 10.3389/fimmu.2015.00529 Andre, 2002, Platelet-derived CD40L: the switch-hitting player of cardiovascular disease, Circulation, 106, 10.1161/01.CIR.0000028962.04520.01 Mobarrez, 2015, CD40L expression in plasma of volunteers following LPS administration: a comparison between assay of CD40L on platelet microvesicles and soluble CD40L, Platelets, 26, 486, 10.3109/09537104.2014.932339 Henn, 1998, CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells, Nature, 391, 591, 10.1038/35393 Andre, 2002, CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism, Nat Med, 8, 247, 10.1038/nm0302-247 Prasad, 2003, Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling, Proc Natl Acad Sci U S A, 100, 12367, 10.1073/pnas.2032886100 Leveille, 2007, CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling, J Biol Chem, 282, 5143, 10.1074/jbc.M608342200 van Kooten, 2000, CD40-CD40 ligand, J Leukoc Biol, 67, 2, 10.1002/jlb.67.1.2 Portillo, 2008, CD40 mediates retinal inflammation and neurovascular degeneration, J Immunol, 181, 8719, 10.4049/jimmunol.181.12.8719 Portillo, 2017, CD40 in retinal muller cells induces P2X7-Dependent cytokine expression in Macrophages/Microglia in diabetic mice and development of early experimental diabetic retinopathy, Diabetes, 66, 483, 10.2337/db16-0051 Lutgens, 1999, Requirement for CD154 in the progression of atherosclerosis, Nat Med, 5, 1313, 10.1038/15271 Mach, 1998, Reduction of atherosclerosis in mice by inhibition of CD40 signalling, Nature, 394, 200, 10.1038/28204 Sanguigni, 2005, Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients, Circulation, 111, 412, 10.1161/01.CIR.0000153810.81187.7D Yacoub, 2010, Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway, Arterioscler Thromb Vasc Biol, 30, 2424, 10.1161/ATVBAHA.110.216143 Blumberg, 2006, An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions, Transfusion, 46, 1813, 10.1111/j.1537-2995.2006.00979.x Bishop, 2007, TRAF proteins in CD40 signaling, Adv Exp Med Biol, 597, 131, 10.1007/978-0-387-70630-6_11 Saemann, 2003, Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3, Am J Transplant, 3, 1341, 10.1046/j.1600-6143.2003.00225.x Saemann, 2002, CD40 triggered human monocyte-derived dendritic cells convert to tolerogenic dendritic cells when JAK3 activity is inhibited, Transplant Proc, 34, 1407, 10.1016/S0041-1345(02)02907-X Elgueta, 2009, Molecular mechanism and function of CD40/CD40L engagement in the immune system, Immunol Rev, 229, 152, 10.1111/j.1600-065X.2009.00782.x Graf, 1995, A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation, Eur J Immunol, 25, 1749, 10.1002/eji.1830250639 Dinarello, 2012, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases, Nat Rev Drug Discov, 11, 633, 10.1038/nrd3800 Sims, 2010, The IL-1 family: regulators of immunity, Nat Rev Immunol, 10, 89, 10.1038/nri2691 Kowluru, 2004, Role of interleukin-1beta in the pathogenesis of diabetic retinopathy, Br J Ophthalmol, 88, 1343, 10.1136/bjo.2003.038133 Baptista, 2017, Elevated glucose and Interleukin-1beta differentially affect retinal microglial cell proliferation, Mediators Inflamm, 10.1155/2017/4316316 Nadeau-Vallee, 2017, Preterm birth and neonatal injuries: importance of Interleukin-1 and potential of Interleukin-1 receptor antagonists, Curr Pharm Des Ghasemi, 2011, Roles of IL-8 in ocular inflammations: a review, Ocul Immunol Inflamm, 19, 401, 10.3109/09273948.2011.618902 Yilmaz, 2016, Relationship between altered platelet morphological parameters and retinopathy in patients with type 2 diabetes mellitus, J Ophthalmol, 10.1155/2016/9213623 Gungor, 2016, The relationship of mean platelet volume with retinopathy in type 2 diabetes mellitus, Turk J Med Sci, 46, 1292, 10.3906/sag-1410-95 Citirik, 2015, MPV may reflect subcinical platelet activation in diabetic patients with and without diabetic retinopathy, Eye (Lond), 29, 376, 10.1038/eye.2014.298 Ayhan Tuzcu, 2014, Relationship between mean platelet volume and retinopathy in patients with type 2 diabetes mellitus, Graefes Arch Clin Exp Ophthalmol, 252, 237, 10.1007/s00417-013-2444-y Babu, 2004, Platelet large cell ratio in the differential diagnosis of abnormal platelet counts, Indian J Pathol Microbiol, 47, 202 Vinik, 2001, Platelet dysfunction in type 2 diabetes, Diabetes Care, 24, 1476, 10.2337/diacare.24.8.1476 Akdogan, 2016, The association of hematologic inflammatory markers with atherogenic index in type 2 diabetic retinopathy patients, Clin Ophthalmol, 10, 1797, 10.2147/OPTH.S110749 Vagdatli, 2010, Platelet distribution width: a simple, practical and specific marker of activation of coagulation, Hippokratia, 14, 28 Bhosle, 2016, Nuclear localization of platelet-activating factor receptor controls retinal neovascularization, Cell Discov, 2, 16017, 10.1038/celldisc.2016.17 Gale, 2017, Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers, PLoS Negl Trop Dis, 11, 10.1371/journal.pntd.0005943 Palur Ramakrishnan, 2017, Platelet activating factor: a potential biomarker in acute coronary syndrome?, Cardiovasc Ther, 35, 64, 10.1111/1755-5922.12233 Jancar, 2014, PAF receptor and tumor growth, Curr Drug Targets, 15, 10.2174/1389450115666140903111812 Joyal, 2015, Subcellular G-protein coupled receptor signaling hints at greater therapeutic selectivity, Expert Opin Ther Targets, 19, 717, 10.1517/14728222.2015.1042365 Agbani, 2017, Membrane ballooning in aggregated platelets is synchronised and mediates a surge in Microvesiculation, Sci Rep, 7, 10.1038/s41598-017-02933-4 Jansen, 2013, High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation, Cardiovasc Res, 98, 94, 10.1093/cvr/cvt013 Wang, 2014, Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets, Acta Pharmacol Sin, 35, 433, 10.1038/aps.2013.188 Falati, 2003, Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin, J Exp Med, 197, 1585, 10.1084/jem.20021868 Zhang, 2017, Pathogenic roles of microvesicles in diabetic retinopathy, Acta Pharmacol Sin Rivera, 2015, BIBF1120 (Vargatef) inhibits preretinal neovascularization and enhances normal vascularization in a model of vasoproliferative retinopathy, Invest Ophthalmol Vis Sci, 56, 7897, 10.1167/iovs.15-17146 Shibuya, 2011, Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for Anti- and pro-angiogenic therapies, Genes Cancer, 2, 1097, 10.1177/1947601911423031 Semenza, 2013, HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations, J Clin Invest, 123, 3664, 10.1172/JCI67230 Gameiro, 2013, In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation, Cell Metab, 17, 372, 10.1016/j.cmet.2013.02.002 Ramakrishnan, 2014, Vascular endothelial growth factor signaling in hypoxia and inflammation, J Neuroimmune Pharmacol, 9, 142, 10.1007/s11481-014-9531-7 Jeltsch, 2013, Receptor tyrosine kinase-mediated angiogenesis, Cold Spring Harb Perspect Biol, 5, 10.1101/cshperspect.a009183 Chang, 2012, Corneal neovascularization: an anti-VEGF therapy review, Surv Ophthalmol, 57, 415, 10.1016/j.survophthal.2012.01.007 Calcutt, 2009, Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials, Nat Rev Drug Discov, 8, 417, 10.1038/nrd2476 Silva, 2010, Effect of systemic medications on onset and progression of diabetic retinopathy, Nat Rev Endocrinol, 6, 494, 10.1038/nrendo.2010.122 Gabbay, 1973, The sorbitol pathway and the complications of diabetes, N Engl J Med, 288, 831, 10.1056/NEJM197304192881609 Ways, 2000, The role of protein kinase C in the development of the complications of diabetes, Vitam Horm, 60, 149, 10.1016/S0083-6729(00)60019-5 Baynes, 1999, Role of oxidative stress in diabetic complications: a new perspective on an old paradigm, Diabetes, 48, 1, 10.2337/diabetes.48.1.1 Kern, 2007, Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy, Exp Diabetes Res, 10.1155/2007/95103 Archer, 1999, Bowman Lecture 1998. Diabetic retinopathy: some cellular, molecular and therapeutic considerations, Eye (Lond), 13, 497, 10.1038/eye.1999.130 Writing Team for the Diabetes C, 2002, Complications Trial/Epidemiology of Diabetes I, Complications Research G. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus, JAMA, 287, 2563, 10.1001/jama.287.19.2563 Poulaki, 2002, Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF, J Clin Invest, 109, 805, 10.1172/JCI0213776 Ryan, 2006, Diabetic macular edema associated with glitazone use, Retina, 26, 562, 10.1097/00006982-200605000-00011 Sun, 2005, Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects, Diabetes, 54, 3418, 10.2337/diabetes.54.12.3418 Superstein, 2000, Prevalence of ocular hemorrhage in patients receiving warfarin therapy, Can J Ophthalmol, 35, 385, 10.1016/S0008-4182(00)80126-X Zheng, 2007, Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy, Diabetes, 56, 337, 10.2337/db06-0789 Fleischman, 2008, Salsalate improves glycemia and inflammatory parameters in obese young adults, Diabetes Care, 31, 289, 10.2337/dc07-1338 Avery, 2006, Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment, Retina, 26, 352, 10.1097/00006982-200603000-00016 Elam, 2000, Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial, Arterial Disease Multiple Intervention Trial. JAMA., 284, 1263 Ye, 2014, Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression, Int J Med Sci, 11, 17, 10.7150/ijms.7329 Panbianco, 2008, A casein kinase 1 and PAR proteins regulate asymmetry of a PIP(2) synthesis enzyme for asymmetric spindle positioning, Dev Cell, 15, 198, 10.1016/j.devcel.2008.06.002 Wang, 2016, MicroRNA-126 contributes to Niaspan treatment induced vascular restoration after diabetic retinopathy, Sci Rep, 6 Ye, 2011, Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats, Exp Neurol, 232, 299, 10.1016/j.expneurol.2011.09.022 van Solingen, 2015, The role of microRNA-126 in vascular homeostasis, Curr Vasc Pharmacol, 13, 341, 10.2174/15701611113119990017 Stitt, 2010, AGEs and diabetic retinopathy, Invest Ophthalmol Vis Sci, 51, 4867, 10.1167/iovs.10-5881 Croci, 2014, Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors, Cell, 156, 744, 10.1016/j.cell.2014.01.043 Kanda, 2017, Advanced glycation endproducts link inflammatory cues to upregulation of galectin-1 in diabetic retinopathy, Sci Rep, 7, 10.1038/s41598-017-16499-8 Larsen, 2007, Interleukin-1-receptor antagonist in type 2 diabetes mellitus, N Engl J Med, 356, 1517, 10.1056/NEJMoa065213 Vincent, 2007, Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia, Diabetes, 56, 224, 10.2337/db06-0427 Durand, 2010, Macrophage activation syndrome treated with anakinra, J Rheumatol, 37, 879, 10.3899/jrheum.091046 Dinarello, 2010, Anti-inflammatory agents: present and future, Cell, 140, 935, 10.1016/j.cell.2010.02.043 Sitaras, 2015, Retinal neurons curb inflammation and enhance revascularization in ischemic retinopathies via proteinase-activated receptor-2, Am J Pathol, 185, 581, 10.1016/j.ajpath.2014.10.020 Hu, 2016, Knockout of Ccr2 alleviates photoreceptor cell death in rodent retina exposed to chronic blue light, Cell Death Dis, 7, 10.1038/cddis.2016.363 Zhang, 2017, Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction, Cell Death Dis, 8, 10.1038/cddis.2017.308 Nalbandian, 2017, Activation of the NLRP3 inflammasome is associated with valosin-containing protein myopathy, Inflammation, 40, 21, 10.1007/s10753-016-0449-5 Shi, 2016, NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component, Nat Immunol, 17, 250, 10.1038/ni.3333 Li, 2006, Interleukin-1beta induction of NFkappaB is partially regulated by H2O2-mediated activation of NFkappaB-inducing kinase, J Biol Chem, 281, 1495, 10.1074/jbc.M511153200 Igarashi, 2003, Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model, Gene Ther, 10, 219, 10.1038/sj.gt.3301878 O’Reilly, 1994, Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma, Cell, 79, 315, 10.1016/0092-8674(94)90200-3 Kim, 2008, Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy, J Cell Mol Med, 12, 2407, 10.1111/j.1582-4934.2008.00243.x Lee, 2005, Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis, J Natl Cancer Inst, 97, 1695, 10.1093/jnci/dji377 Palazon, 2017, An HIF-1alpha/VEGF-A Axis in cytotoxic t cells regulates tumor progression, Cancer Cell, 32, 669, 10.1016/j.ccell.2017.10.003 Webb, 2009, Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing, Cell Mol Life Sci, 66, 3539, 10.1007/s00018-009-0147-7 Huang, 2011, Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration, Invest Ophthalmol Vis Sci, 52, 7565, 10.1167/iovs.11-8002 Fraisl, 2009, Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease, Nat Rev Drug Discov, 8, 139, 10.1038/nrd2761 Zhang, 2015, Effects of p75 neurotrophin receptor on regulating hypoxia-induced angiogenic factors in retinal pigment epithelial cells, Mol Cell Biochem, 398, 123, 10.1007/s11010-014-2212-2 Sheedlo, 2002, Expression of p75(NTR) in photoreceptor cells of dystrophic rat retinas, Brain Res Mol Brain Res, 103, 71, 10.1016/S0169-328X(02)00185-7 Caporali, 2008, Neurotrophin p75 receptor (p75NTR) promotes endothelial cell apoptosis and inhibits angiogenesis: implications for diabetes-induced impaired neovascularization in ischemic limb muscles, Circ Res, 103, 10.1161/CIRCRESAHA.108.177386 Strauss, 2005, The retinal pigment epithelium in visual function, Physiol Rev, 85, 845, 10.1152/physrev.00021.2004 Jo, 2006, Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization, Am J Pathol, 168, 2036, 10.2353/ajpath.2006.050588 Gomi, 2008, Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy, Br J Ophthalmol, 92, 70, 10.1136/bjo.2007.122283 Gschwind, 2004, The discovery of receptor tyrosine kinases: targets for cancer therapy, Nat Rev Cancer, 4, 361, 10.1038/nrc1360 Wilkinson-Berka, 2004, Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy, Am J Pathol, 164, 1263, 10.1016/S0002-9440(10)63214-2 Hilberg, 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy, Cancer Res, 68, 4774, 10.1158/0008-5472.CAN-07-6307 Ishimaru, 2017, An apelin receptor antagonist prevents pathological retinal angiogenesis with ischemic retinopathy in mice, Sci Rep, 7, 10.1038/s41598-017-15602-3 Tatemoto, 1998, Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor, Biochem Biophys Res Commun, 251, 471, 10.1006/bbrc.1998.9489 Kasai, 2008, Retardation of retinal vascular development in apelin-deficient mice, Arterioscler Thromb Vasc Biol, 28, 1717, 10.1161/ATVBAHA.108.163402 Kidoya, 2010, Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia, Blood, 115, 3166, 10.1182/blood-2009-07-232306 del Toro, 2010, Identification and functional analysis of endothelial tip cell-enriched genes, Blood, 116, 4025, 10.1182/blood-2010-02-270819 Kasai, 2013, Inhibition of apelin expression switches endothelial cells from proliferative to mature state in pathological retinal angiogenesis, Angiogenesis, 16, 723, 10.1007/s10456-013-9349-6 Metin, 2017, Evaluation of the plasma microRNA levels in stage 3 premature retinopathy with plus disease: preliminary study, Eye (Lond) van Mil, 2012, MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release, Cardiovasc Res, 93, 655, 10.1093/cvr/cvs003 Ferrara, 2016, Ten years of anti-vascular endothelial growth factor therapy, Nat Rev Drug Discov, 15, 385, 10.1038/nrd.2015.17 Saharinen, 2017, Therapeutic targeting of the angiopoietin-TIE pathway, Nat Rev Drug Discov, 16, 635, 10.1038/nrd.2016.278 Frye, 2015, Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin, J Exp Med, 212, 2267, 10.1084/jem.20150718 Eklund, 2013, Angiopoietin signaling in the vasculature, Exp Cell Res, 319, 1271, 10.1016/j.yexcr.2013.03.011 Koh, 2013, Orchestral actions of angiopoietin-1 in vascular regeneration, Trends Mol Med, 19, 31, 10.1016/j.molmed.2012.10.010 Gamble, 2000, Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions, Circ Res, 87, 603, 10.1161/01.RES.87.7.603 Benest, 2013, Angiopoietin-2 is critical for cytokine-induced vascular leakage, PLoS One, 8, 10.1371/journal.pone.0070459 Ghosh, 2015, Drug repurposing screen identifies Foxo1-Dependent Angiopoietin-2 regulation in Sepsis, Crit Care Med, 43, 10.1097/CCM.0000000000000993 Korhonen, 2016, Tie1 controls angiopoietin function in vascular remodeling and inflammation, J Clin Invest, 126, 3495, 10.1172/JCI84923 Kanofsky, 1989, Singlet oxygen production by biological systems, Chem Biol Interact, 70, 1, 10.1016/0009-2797(89)90059-8 Park, 2014, Angiopoietin 2 induces pericyte apoptosis via alpha3beta1 integrin signaling in diabetic retinopathy, Diabetes, 63, 3057, 10.2337/db13-1942 Cascone, 2005, Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1, J Cell Biol, 170, 993, 10.1083/jcb.200507082 Simon, 2008, The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1, J Cell Physiol, 217, 809, 10.1002/jcp.21558 Bartlett, 2016, Vascular growth factors and glomerular disease, Annu Rev Physiol, 78, 437, 10.1146/annurev-physiol-021115-105412 Qiu, 2016, Nucleoside diphosphate kinase B deficiency causes a diabetes-like vascular pathology via up-regulation of endothelial angiopoietin-2 in the retina, Acta Diabetol, 53, 81, 10.1007/s00592-015-0752-x Hammes, 2004, Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy, Diabetes, 53, 1104, 10.2337/diabetes.53.4.1104 Jeansson, 2011, Angiopoietin-1 is essential in mouse vasculature during development and in response to injury, J Clin Invest, 121, 2278, 10.1172/JCI46322 Stiehl, 2014, Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis, Crit Care Med, 42, 10.1097/CCM.0000000000000524 Han, 2016, Amelioration of sepsis by TIE2 activation-induced vascular protection, Sci Transl Med, 8, 10.1126/scitranslmed.aad9260 Lee, 2013, Angiopoietin-1 guides directional angiogenesis through integrin alphavbeta5 signaling for recovery of ischemic retinopathy, Sci Transl Med, 5, 10.1126/scitranslmed.3006666 Banno, 2017, Tissue regeneration using endothelial colony-forming cells: promising cells for vascular repair, Pediatr Res Connor, 2009, Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis, Nat Protoc, 4, 1565, 10.1038/nprot.2009.187 Medina, 2010, Outgrowth endothelial cells: characterization and their potential for reversing ischemic retinopathy, Invest Ophthalmol Vis Sci, 51, 5906, 10.1167/iovs.09-4951 Sakimoto, 2017, CD44 expression in endothelial colony-forming cells regulates neurovascular trophic effect, JCI Insight, 2, 10.1172/jci.insight.89906 Shirley Ding, 2016, Revisiting the role of erythropoietin for treatment of ocular disorders, Eye (Lond), 30, 1293, 10.1038/eye.2016.94 Chateauvieux, 2011, Erythropoietin, erythropoiesis and beyond, Biochem Pharmacol, 82, 1291, 10.1016/j.bcp.2011.06.045 Garcia-Ramirez, 2008, Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects, Diabetes Care, 31, 1189, 10.2337/dc07-2075 Chang, 2013, Erythropoietin protects adult retinal ganglion cells against NMDA-, trophic factor withdrawal-, and TNF-alpha-induced damage, PLoS One, 8, 10.1371/journal.pone.0055291 Wang, 2009, Erythropoietin protects retinal pigment epithelial cells from oxidative damage, Free Radic Biol Med, 46, 1032, 10.1016/j.freeradbiomed.2008.11.027 Savino, 2006, Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis, J Neuroimmunol, 172, 27, 10.1016/j.jneuroim.2005.10.016 Zhang, 2008, Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes, Invest Ophthalmol Vis Sci, 49, 732, 10.1167/iovs.07-0721 Chen, 2008, Erythropoietin deficiency decreases vascular stability in mice, J Clin Invest, 118, 526 Ramirez, 2009, Carbamylated darbepoetin derivative prevents endothelial progenitor cell damage with no effect on angiogenesis, J Mol Cell Cardiol, 47, 781, 10.1016/j.yjmcc.2009.09.005 Liu, 2015, Carbamylated erythropoietin mediates retinal neuroprotection in streptozotocin-induced early-stage diabetic rats, Graefes Arch Clin Exp Ophthalmol, 253, 1263, 10.1007/s00417-015-2969-3